[Is there a role for calcium antagonists when beta-adrenergic blockade therapy is contraindicated in post-myocardial infarction?].
The purpose of this paper is to examine the eventual benefits of treatment with calcium channel blockers in post-myocardial infarction, through an overview of main placebo-controlled trials that have been conducted to test this therapeutic in acute coronary syndromes. It appears obvious that the vast majority of these trials was conducted in the pre-reperfusion era and failed to demonstrate a reduction in mortality. To conclude, the superiority of a therapy with calcium antagonists over a placebo in the management of post-myocardial infarction remains unknown. In contrast, adverse effects associated with the prescription of calcium antagonists are well known.
Ennezat
Pierre-Vladimir
PV
Hôpital cardiologique, Lille, France. pv-ennezat@chru-lille.fr
Auffray
Jean-Luc
JL
Darchis
Julie
J
Rousselle
Maxime
M
Gonin
Xavier
X
Aubert
Jean-Marc
JM
Bauchart
Jean-Jacques
JJ
Bauters
Christophe
C
Van Belle
Eric
E
Asseman
Philippe
P
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D000075202:Contraindications; D004110:Diltiazem / Q000627:therapeutic use; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy*; D009543:Nifedipine / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine